Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Cand5 enters phase I study for AMD

Oct. 14, 2004

Photrex chosen as new brand name for SnET2

Oct. 11, 2004

Squalamine granted fast track status for wet AMD

Oct. 7, 2004

Therapeutic benefits of omalizumab in allergy conjunctivitis

Oct. 6, 2004

Approvable letter for SnET2 for AMD

Oct. 5, 2004

ISTA and Allergan sign new Vitrase agreement

Oct. 4, 2004

Expanded phase II trial for squalamine opens enrollment

Oct. 1, 2004

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

The EMEA accepts marketing authorization application for Macugen

Sep. 23, 2004

Approvable letter for Extravan for glaucoma

Sep. 21, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...